|
ChinaXiv of Chinese Academy of Sciences and F1000 of Taylor & Francis jointly launched a pilot program on open peer review and publication of preprints Author Invitations Dear authors: In 2022, the National Science Library of the Chinese Academy of Sciences signed a MOU with F1000, the open research publishing arm of Taylor & Francis, to jointly explore and construct, a new academic publishing model of ‘validated preprint-open peer review-publication’. To implement this collaboration, ChinaXiv is working with F1000 and Taylor & Francis on a pilot program which is exploring open peer review and the publication of preprints in oncology. The project aims to facilitate the priority release of oncology research results, improve the quality of research, and promote open and transparent publication. We sincerely hope you will participate in this pilot program and invite you to publish your preprints on the ChinaXiv platform. Your preprints will be subject to an open editorial process, including open peer review and open data sharing, supported by F1000 and Taylor & Francis. All peer review reports, including the names of the reviewers, will be published on ChinaXiv and linked to your preprints. The preprints that pass peer review will be directly published in the Oncology section of the Annals of Medicine, which is an international OA journal of General Practice (2022 impact factor: 4.4).
本项目合作期刊 1、International Journal of Nanomedicine （2023 impact factor: 6.6） https://www.tandfonline.com/journals/dijn20 2、Annals of Medicine （2023 impact factor: 4.9）https://www.tandfonline.com/journals/iann20 3、Journal of Inflammation Research （2023 impact factor: 4.2）https://www.tandfonline.com/journals/djir20 4、Breast Cancer: Targets and Therapy （2023 impact factor: 3.3） https://www.tandfonline.com/journals/dbct20 5、Clinical Pharmacology: Advances and Applications（2023 impact factor: 3.1） https://www.tandfonline.com/journals/dcpa20 6、International Journal of Nephrology and Renovascular Disease（2023 impact factor: 2.1） https://www.tandfonline.com/journals/dnrd20 7、Integrated Pharmacy Research and Practice （2023 impact factor: 2.1）https://www.tandfonline.com/journals/dipr20 8、Patient Preference and Adherence （2023 impact factor: 2.1）https://www.tandfonline.com/journals/dppa20 9、Nursing: Research and Reviews （2023 impact factor: 0.8） https://www.tandfonline.com/journals/dnrr20 10、Pharmacogenomics and Personalized Medicine （2023 impact factor: 1.8） https://www.tandfonline.com/journals/dpgp20 11、Journal of Experimental Pharmacology (2023 CiteScore (Scopus)impact factor7.4） https://www.dovepress.com/journal-of-experimental-pharmacology-journal If you would like to participate in this pilot program, please express your interest to ChinaXiv by emailing: eprint@mail.las.ac.cn; or tel: 010-82626611-6753. Once you have expressed your interest, we will provide you with more details on how the pilot program works and will assist you with your participation. To ensure that the pilot program can be carried out as scheduled, please publish your preprints in oncology on ChinaXiv . Click to view the paper for this project
|
